Aberystwyth University Confocal Microscopy Article Discussion

User Generated

Wnore07

Science

Aberystwyth University

Question Description

Can you help me understand this Chemistry question?

Can you please analyze figure 2A from the attached article? 

And write me the goal of the article  and what interest you from the aticle and what concerns or questions you have about the article? 

Unformatted Attachment Preview

Articles Cite This: ACS Chem. Biol. 2019, 14, 636−643 pubs.acs.org/acschemicalbiology Reverse Chemical Proteomics Identifies an Unanticipated Human Target of the Antimalarial Artesunate Michael P. Gotsbacher,†,⊥,§ Sung Min Cho,‡,⊥ Nam Hee Kim,‡ Fei Liu,† Ho Jeong Kwon,*,‡ and Peter Karuso*,† † Department of Molecular Sciences, Macquarie University, Sydney, NSW 2109, Australia Chemical Genomics Global Research Laboratory, Department of Biotechnology, College of Life Science & Biotechnology, Yonsei University, 50 Yonsei-ro, Seodaemun-gu, Seoul 120-749, South Korea Downloaded via DEPAUL UNIV on February 10, 2020 at 02:33:44 (UTC). See https://pubs.acs.org/sharingguidelines for options on how to legitimately share published articles. ‡ S Supporting Information * ABSTRACT: Artemisinins are the most potent and safe antimalarials available. Despite their clinical potential, no human target for the artemisinins is known. The unbiased interrogation of several human cDNA libraries, displayed on bacteriophage T7, revealed a single human target of artesunate; the intrinsically disordered Bcl-2 antagonist of cell death promoter (BAD). We show that artesunate inhibits the phosphorylation of BAD, thereby promoting the formation of the proapoptotic BAD/Bcl-xL complex and the subsequent intrinsic apoptotic cascade involving cytochrome c release, PARP cleavage, caspase activation, and ultimately cell death. This unanticipated role of BAD as a possible drug target of artesunate points to direct clinical exploitation of artemisinins in the Bcl-xL life/death switch and that artesunate’s anticancer activity is, at least in part, independent of reactive oxygen species. T of artemisinin is activated and cleaved through a hemedependent, radical mechanism that alkylates parasite proteins.18−20 This has recently been supported through chemical proteomics investigations in which at least 124 parasite proteins were shown to be alkylated by an artesunate analogue in infected red blood cells.21 Notwithstanding this, proposed specific targets include SERCA,22 membrane glutathione Stransferase (PfEXP1),23 or phosphatidylinositol-3-kinase PfPI3K in P. falciparum.24 Interestingly, artemisinins display polypharmacology with profound and selective anticancer activity25,26 and, it has been suggested, promote apoptosis via mitochondrial pathways in cancer cell lines.27−29 It is known that many genes are upregulated upon 1 treatment in cancer cell lines. These include BUB3, cyclins, CDC25A (proliferation), VEGF, MMP9, angiostatin, thrombospondin-1 (angiogenesis), and Bcl-2, BAX, and NF-κB (apoptosis).27,30 Despite their clinical potential for treating cancer and the extensive primary literature on their anticancer activity, 1’s human target remains elusive.31−34 he study of weak but selective protein−ligand interactions has always been a challenge and is exemplified by gamma-hydroxybutyric acid, which is a 3 mM agonist of GABA-B receptors but highly selective.1 Low affinity effectively hinders the identification of small molecule protein targets using genome-wide, forward proteomic methods such as affinity capture MS or affinity chromatography.2 Even high affinity interactions can be problematic to identify in the presence of large amounts of nonspecific interactions. An attractive alternative approach, particularly suited for weak interactions with low abundance proteins, is reverse chemical proteomics using phage display where there is a physical link between the genome and proteome.3−13 The rapid life cycle of bacteriophages allows iterative purification of rare and/or low abundance proteins from highly complex mixtures based on relatively weak affinity to a tagged small molecule. For example, we were able to rapidly isolate a human protein target for kahalalide F that showed ∼50 μM KD with ribosomal protein S25.9 Here, we report the identification of the Bcl-2 agonist of cell death (BAD) promotor as the first human target of the natural product drug artesunate (1) using T7 phage display. Artemisinins are sesquiterpenes from the sweet wormwood (Artemisia annua).14,15 They are the most potent antimalarials available with 500 million doses/annum prescribed to eradicate Plasmodium falciparum infections,16 but their mode of action is still under debate.17 It is, however, widely accepted that inside the infected red blood cell, the endoperoxide bridge © 2019 American Chemical Society ■ RESULTS AND DISCUSSION We began with the synthesis of a biotinylated analogue (3) of 1 from artemisinin (2) containing a long, hydrophilic linker Received: November 13, 2018 Accepted: March 6, 2019 Published: March 6, 2019 636 DOI: 10.1021/acschembio.8b01004 ACS Chem. Biol. 2019, 14, 636−643 Articles ACS Chemical Biology not converge (Figure 1A; Figure S4). For all four tumor libraries, the phage titer increased exponentially after round 8 Scheme 1. Synthesis of Probes and NMR Correlations for Probe 3a Figure 1. BAD is the common protein binding partner of 1, identified by biopanning of phage displayed cDNA libraries from various cancer cells. (A) Agarose gel electrophoresis of phage DNA inserts, amplified by PCR from phage sublibraries after biopanning against 5 immobilized on neutravidin-coated microtiter plates. See Figures S4 and S5 for more detail. (B) Phage titer after each round of biopanning showing convergence after rounds 8−10 for the 4 tumor cDNA libraries and (C) on-phage binding study showing 100-fold higher titer of the BAD-displaying phage clone for the 1-immobilized support than the support with immobilized negative control (4). The wildtype phage (no insert) does not differentiate the two supports. (e.g., Figure 1C). Random plaques were picked after the last round and fingerprinted by Hinf1 digestion (Figure S5). From sequencing, in all converged tumor libraries, the dominant clone (Table S4) was the Bcl-2 antagonist of cell death promoter (BAD). Comparison of the DNA sequences showed that for each library the phage selection produced BAD clones of different lengths, but all were in-frame with the phage coat protein and covered the full coding sequence of BAD (Table 1). No other gene was represented by in-frame clones that appeared in more than one tumor library. Several attempts to clone and overexpress BAD as hexaHis or GST fusions failed due to the intrinsic disorder of the BAD protein.36 Attempted purification led to extensive degradation, so it was not possible to obtain a pure sample for reliable KD measurements. Consequently, an on-phage binding assay (Figure 1C) was used and showed that the control phage (no insert) produced a background of ∼107 phage particles upon elution with SDS in wells derivatized with 3 or 4. In contrast, BAD-phage (with BAD insert) produced 100× more phage particles upon elution from 3-derivatized wells compared to 4, suggesting a specific interaction between BAD and 1. As an alternative to quantitative KD measurements, we constructed a peptide library of BAD peptides (31 × 20mers shifted by 5 aa each time; Table S5) arrayed onto a glass slide. Staining with 6, with butylamine-NBD as a negative control (Figure S13), indicated preferential binding of 6 to a section around S136, just before the BH3 domain, and to the C-terminal of the protein (Figure S14). BAD, as a BH3-only, proapoptotic protein, was originally identified as a partner for Bcl-2 and Bcl-xL in a yeast twohybrid screen and shown to displace BAX to induce cytochrome c release and caspase-dependent apoptosis.37 To a Red = HMBC, green = ROESY, black = COSY, showing key correlations only. Reagents and conditions: (a) 2, NaBH4 (3.5 equiv)/MeOH, 0−5 °C, 2 h, 81% yield; (b) 5, succinic anhydride (1.6 equiv), imidazole (0.9 equiv)/DCM, rt 2 h, 91% yield; (c) biotinPEG-NH2, 1 (2 equiv), EDC (4 equiv), HOBt (4 equiv)/DMF, 0 °C over 30 min, then rt 18 h, then excess water, 39% yield; (d) biotinPEG-NH2, valeric acid (2 equiv), EDC (3 equiv), HOBt (3 equiv)/ DMF, 0 °C over 30 min, then rt 18 h, then excess water, 28% yield; (e) NBD-Cl (1.2 equiv)/ACN, β-alanine (1.2 equiv), and NaHCO3 (3 equiv)/water, 55 °C, 1 h; then remove ACN, pH to 2 (1 N HCl); solvent removal, then 5 (1 equiv)/DCM, DMAP (1.2 equiv) under N2; then EDC (1.2 equiv), rt 18 h, 42% yield over two steps. (biotin-PEG-NH2; Scheme 1). Derivatization at C12 is known to not affect the anticancer activity of artemisinins.35 The structure, purity, stereochemistry, and stability were verified by HPLC, NMR spectroscopy, and HRMS (Scheme 1; Figures S1 and S2). Likewise, a biotinylated “blank probe” reagent (4) was synthesized from valeric acid, along with 6, a fluorescent analogue of 1 for imaging (F-ART, Scheme 1; Figure S3). Compounds 3 and 4 were immobilized in separate neutravidin coated microtiter strip wells. Five human cDNA libraries, expressed in bacteriophage T7, were panned against 3-coated wells, after preclearing in 4-coated wells to remove nonspecific binders. After 9 rounds of biopanning, all four tumor libraries produced dominant clones but the normal colon library did 637 DOI: 10.1021/acschembio.8b01004 ACS Chem. Biol. 2019, 14, 636−643 Articles ACS Chemical Biology Table 1. Sequence Alignment of BAD Clones from Colon Tumor (CoT), Liver Tumor (LiT), Lung Tumor (LuT) and Breast Tumor (BrT) cDNA Phage Libraries and Consensus with Human BADa a The BH3 domain of BAD is highlighted in blue and the phosphorylated Ser residues in green. Each library converged on full-length BAD with many different clones varying in N- and C-terminal sequences, but all were in-frame with the coat protein. The bolded/underlined residues are the consensus binding domains from the peptide dot blot experiments (see Table S5, Figures S13 and S14). bThe mouse numbering system is widely used in the literature and is 36 amino acids longer than human BAD. Thus, S99 above is S136 in the mouse sequence, and to avoid confusion, the mouse numbering is used throughout. mL−1) and 1 (0 to 400 μM) concentrations, following the literature recommendations to apply 10× higher ligand concentrations as the upper limit compared to the effective concentration.38 For actin (Figure 3D) and BAX (Figure 3C), hydrolysis proceeded in a 1-independent manner. In contrast, BAD was more readily proteolyzed in a clear dose-dependent manner (Figure 3B; p = 0.0063), suggesting that 1 selectively binds to BAD but not the related BAX protein or the actin loading control. The proapoptotic action of 1 was abrogated when BAD expression was knocked down using a mixture of four siRNAs against BAD (siBAD) (Figure 4). In the presence of 20 nM siBAD, BAD expression in HeLa cells was reduced by ∼60% compared to random siRNA (Figures 4A and 4B). Compound 1’s apoptotic effect increased in a time- and dose-dependent manner (Figure 4C) that was only slightly affected by the introduction of a mixture of random siRNA (Figure 4D). In cells treated with siBAD with 40 μM 1, the suppression of 1’s apoptotic effect was significant (87% cells surviving with BAD knock-down vs 65% without; Figure 4E). The loss of 1’s apoptotic effect with 20 nM siBAD was most prominent after 72 h of growth (71% surviving with BAD knock-down vs 20% without; Figure 4E). The same effect was observed for all concentrations of 1 tested again in a dose-dependent manner (p = 0.055). In contrast, the apoptotic effect of camptothecin was not responsive to changes of BAD expression (Figure S11C) because camptothecin induces apoptosis by targeting topoisomerase I.39 validate the dependence of 1’s apoptotic activity on BAD, cell proliferation assays were performed first using HeLa (human cervical cancer) cells (Figure S6), providing LD50 values of 63, 38, and 12 μM (R2 = 0.94−0.98) for 24, 48, and 72 h 1 treatments, respectively, and established upper limits on the concentrations of 1 that can be used in live cells. The apoptotic effect of 1 was also confirmed in HeLa cells by observation of a dose-dependent release of cytochrome c into the cytosol, PARP cleavage, and caspase activation (Figures S7−S9). Under the microscope, cells treated with ≥10 μM 1 showed typical signs of apoptosis (Figure S12). The binding of ART to BAD was further investigated in HeLa cells through confocal microscopy. To investigate the binding of ART to BAD in living cells, F-ART (6) was synthesized and used in a competitive binding assay. Cells that were pretreated with unlabeled ART (1) and then stained with 6 (Figure 2A, panel 2), showing a 60% reduction in fluorescence, demonstrating that 6 and 1 share the same binding site in the cytosol of HeLa cells (Figure 2A). BAD and 6 were also found to partially colocalize in the cytosol of HeLa cells (Figure 2B), and there is a positive correlation (r2 > 0.75) between the localization of 6 and BAD-Ab, suggesting that 6 and 1 bind to BAD in living cells. Similar results were obtained for HEK293 cells (Figure S12). A DARTS assay with HEK293 cell lysates (Figure 3), in which the binding of a ligand to a protein is detected by either the enhanced or reduced rate of proteolysis,38 suggested the binding of 1 to BAD. The proteolysis of BAD, BAX, and actin in the cell lysate was monitored in the presence of increasing Pronase (0 to 10 μg 638 DOI: 10.1021/acschembio.8b01004 ACS Chem. Biol. 2019, 14, 636−643 Articles ACS Chemical Biology Figure 4. Validation of the interaction between 1 and BAD using siRNA. (A) BAD can be knocked down in live HeLa cells with 20 nM mixture of 4 siRNAs for BAD (lane 3) relative to random mixed siRNA (lane 2). (B) Graphical representation of (A) carried out in triplicate. (C) Percentage (relative to control) cell survival of HeLa cells treated with variable 1 for 2472 h. (D) Same as B except HeLa cells were also treated with a 20 nM mixture of random siRNA. (E) The same as D except cells were treated with 20 nM siRNA against BAD. ***Designates p < 0.001 (Student’s t-test). various derivatives) has been reported, but no target was identified.42 More recently, Button et al. argued that necroptosis is 1’s main mode of action on Schwannoma cells.43 Even more recently, Hamacher suggests “ferroptosis” in pancreatic cancer cells and that 1 did not induce apoptosis or necroptosis.44 A recent chemical proteomics study in this journal suggested that due to heme activation, 1 covalently modified many proteins (in HeLa cell lysates treated with 10 μM hemin) to achieve its anticancer activity in parallel to its antimalarial activity.45 However, this is not consistent with other studies that discount oxidative damage as necessary for cytotoxicity of 1 and demonstrate 1-induced apoptosis in a ROS-independent, Bax-mediated manner.46 The use of a cell lysate with a high concentration of added hemin is also not physiologically relevant. The endoperoxide of ART is known to react with free hemin.47 Our identification of BAD as a target of 1 opens new questions in ROS-independent apoptosis and potential avenues for targeted therapies. Given that targeting Bcl-2/Mcl-1 family members is an emerging strategy in development of anticancer therapeutics48 and these life/ death switches have been suggested as the Achilles’ heel of many tumors,49 a BAD-targeted mechanism of action for 1 in a specific apoptotic pathway could lead to synergy with other anticancer therapies.50 BAD can reverse the pro-survival activity of Bcl-xL but not that of Bcl-2. Also, in rat ovaries, mutation of BADS136A results in the reported binding of BAD to Mcl-1, whereas wild-type phosphorylated BAD binds exclusively to 14-3-3.51 Regulation of BAD is achieved by cytokine and growth factor signaling and likely influences numerous aspects of metabolism, autophagy, and apoptosis.48,52 In a breast cancer model where PTEN is mutated, BAD is constitutively phosphorylated and sequestered by 14-3-3, completely inhibiting its proapoptotic activity.53 In AML, it was found that BAD was phosphorylated at S112 and S136 in 41/42 clinical samples tested.54 BAD’s sensitizer activity toward apoptosis is negatively regulated by kinases (JNK, PKA, and AKT) through phosphorylation at S112, S136, and S155.55−57 It has been suggested the phosphorylation within the BH3 domain (S155; Table 1) renders the binding of BAD to the hydrophobic BH3 Figure 2. Validation of the interaction between 1 and BAD using fluorescently labeled 1 (F-ART, 6). (A) Competition between 1 (ART) and 6 (F-ART). Panel 1: Treatment of HeLa cells with Hoechst (blue) and 6 (green). Panel 2: Treatment of HeLa cells with Hoechst (blue) and 6 (green) in the presence of 25 μM 1. The intensity of 6 was measured using Image J and displayed as a bar graph. (B) Colocalization of 6 (green) and BAD-Ab (red). Panels 1 and 2: Treatment of HeLa cells with Hoechst (blue) and 10 μM 6 (green) and BAD-Ab (red). Panel 3: Additional cells. The colocalization of F-ART and BAD was measured using Image J and expressed as a Pearson correlation curve. Figure 3. Validation of the interaction between 1 and BAD using the DARTS assay. (A) Western blotting of BAD, BAX, and actin (loading control) with variable 1 and Pronase. (B−D) Graphical representation of (B) for BAD (p = 0.00152; one-way ANOVA), BAX (p = 0.8968), and actin (p = 0.6592), respectively, run in triplicate. **Designates p < 0.01 (Student’s t-test). The identification of BAD as a target of 1’s apoptotic effect came as a surprise. Many mechanisms for the anticancer activity of artemisinins have been proposed with reactive oxygen species (ROS) generation or mitochondrial induced apoptosis, involving Bcl-2 family genes, particularly prominent in the literature.33,40,41 A cell line-dependent effect of 1 (or its 639 DOI: 10.1021/acschembio.8b01004 ACS Chem. Biol. 2019, 14, 636−643 Articles ACS Chemical Biology (Figure 6A), even though BAD and ABT-737 both putatively bind Bcl-xL to achieve their apoptotic effect. As the apparent cytotoxicity of 1 is abrogated if BAD is knocked down in HeLa cells (Figure 4) and the level of pBAD decreases in a dose-dependent way with siBAD (Figure 5), this suggests that binding to BAD is required for 1’s apoptotic effect and that ROS are not necessarily involved in 1’s anticancer activity. Because phosphorylation is a major regulatory mechanism by which cancer cells inhibit BAD function to suppress apoptosis, an elegant way to restore BAD activity, and thus the sensitivity of cells to apoptotic signaling without affecting the critical roles of kinases through kinasebased drugs, would be to inhibit only the phosphorylation of BAD. From our results, it is possible that this is indeed how 1 achieves its proapoptotic activity in HeLa cells. Theoretically, 1’s binding to BAD can either stabilize the Bcl-xL−BAD interaction, reduce the sequestration of pBAD by 14-3-3 proteins (leaving free pBAD susceptible to phosphatases), or inhibit the phosphorylation of BAD, which favors the formation of the proapoptotic Bcl-xL−BAD complex. While our observations (Figure 1C, Figure S14) support the last mode of action, the first two possibilities remain to be refuted. The combined effects of 1 and ABT-737, a BH3 mimic that binds to Bcl-2, Bcl-xL, and Bcl-w but not Mcl-1,59 surprisingly revealed a highly synergistic action (Figure 6). HeLa cells are resistant to ABT-737 (LD50 > 200 μM) because of high levels of Mcl-1. Our results suggest that the dephosphorylation (or inhibition of phosphorylation) of BAD by 1 results in a marked increase in sensitivity of HeLa cells to ABT-737 (LD50 16 μM) in the presence of 10 μM 1 and 1.2 μM with 20 μM 1. This synergy suggests that 1 may do more than just promote the binding of BAD to Bcl-xL, and we anticipate that this target identification will enable the future exploration of many of these interesting possibilities in the clinic. Intrinsically disordered proteins (such as BAD) have the potential to bind to multiple partners depending on their conformation and post-translational modifications. Future clinical investigations of how 1 may sensitize tumors to other genotoxic agents will shed more light on the tumor selectivity of 1 and inform clinical repositioning of this fascinating natural product. Indeed, it is known that 1 synergistically induces apoptosis of HeLa cells after IR but not SiHa cells 60 and dihydroartemisinin (5) synergistically induces apoptosis in OVCAR-3 and A2780 (but not IOSE144) ovarian cancer cells treated with carboplatin.61 Similarly, A2780, HO8910, and HEY ovarian cancer cells responded to 1 in a dose-dependent manner and are synergistic with carboplatin, but SKOV3 cells were totally unresponsive to 1.62 1 has also been reported to sensitize breast cancer cells to the chemotherapeutic agent epirubicin.63 Follow-up studies will include further characterization of the interaction between ART and BAD using other biophysical techniques and phosphoproteomics. The synergy between ART and AZD-59912 and S63845 (inhibitors of Mcl-1) and the interaction of ART with other BH3-only proteins will help to further characterize the cellular mechanism of ART that would not be obvious without first identifying BAD as a target of ART. In summary, phage display is an underutilized but powerful technique for the genome wide, unbiased, reverse chemical proteomics identification of potential protein targets of small molecules. We have identified the Bcl-2 associate death promoter (BAD) as a possible human target of artesunate binding domain of Bcl-xL unfavorable, resulting in inhibition of BAD’s proapoptotic function.58 The level of S136-pBAD was therefore measured in HeLa cells 24 h after treating with 1 (0− 40 μM) or camptothecin (positive control; 1−10 μM) (Figure 5A). A dose-dependent decrease in phosphorylation on S136 Figure 5. 1 reduces the level of S136 phosphorylation on BAD and Bcl-xL expression levels in HeLa cells. (A) Dose-dependent reduction in S136 phosphorylation on BAD in HeLa cells on treatment with 1. (B) Graphical representation of (A) carried out in triplicate. (C) Dose-dependent reduction of Bcl-xL expression levels upon 1 treatment. (D) Graphical representation of (C) carried out in triplicate. *Designates p < 0.05, **designates p < 0.01, ***designates p < 0.001 (Student’s t-test). was observed (Figure 5B) with 1, consistent with the peptide array data (Figures S13 and S14). There was also a dosedependent decrease in the expression levels of Bcl-xL (Figures 5C and 5D). At 20 μM, BAD phosphorylation was reduced by 60% and Bcl-xL by 20%. The effect of fixed doses of 1 on HeLa cells in the presence of 0, 0.01, 0.1, 1, or 10 μM ABT-737 or camptothecin was subject to isobolographic analysis (Figure 6) to determine if 1 Figure 6. 1 is synergistic with ABT-737 and camptothecin. (A) Isobole analysis (from Figures S15A−C) of the interaction between 1 and ABT-737 shows a strong synergistic effect at 10 μM (square) and 20 μM (diamond) 1. (B) Isobole analysis (from Figures S15d−f) of the interaction between 1 and camptothecin also shows a synergistic effect at 10 μM (square) and 20 μM (diamond). would work synergistically or additively with ABT-737, a clinically useful, known BH3-mimic that binds Bcl-xL.59 HeLa cells were grown for 24 or 48 h after treatment and the LD50 determined in the presence or absence of 1 (Figure S15). As expected, 1 and camptothecin are synergistic (Figure 6B) as they target orthogonal pathways, but surprisingly, 1 and ABT737 camptothecin were also found to be highly synergistic 640 DOI: 10.1021/acschembio.8b01004 ACS Chem. Biol. 2019, 14, 636−643 Articles ACS Chemical Biology (AE-MS) Rather than Affinity Purification Mass Spectrometry (APMS). Mol. Cell. Proteomics 14, 120. (3) McKenzie, K. M., Videlock, E. J., Splittgerber, U., and Austin, D. J. (2004) Simultaneous Identification of Multiple Protein Targets by Using Complementary-DNA Phage Display and a Natural-ProductMimetic Probe. Angew. Chem., Int. Ed. 43, 4052−4055. (4) Boehmerle, W., Splittgerber, U., Lazarus, M. B., McKenzie, K. M., Johnston, D. G., Austin, D. J., and Ehrlich, B. E. (2006) Paclitaxel induces calcium oscillations via an inositol 1,4,5-trisphosphate receptor and neuronal calcium sensor 1-dependent mechanism. Proc. Natl. Acad. Sci. U. S. A. 103, 18356−18361. (5) Izaguirre-Carbonell, J., Kawakubo, H., Murata, H., Tanabe, A., Takeuchi, T., Kusayanagi, T., Tsukuda, S., Hirakawa, T., Iwabata, K., Kanai, Y., Ohta, K., Miura, M., Sakaguchi, K., Matsunaga, S., Sahara, H., Kamisuki, S., and Sugawara, F. (2015) Novel anticancer agent, SQAP, binds to focal adhesion kinase and modulates its activity. Sci. Rep. 5, 15136. (6) Jung, H. J., Shim, J. S., Lee, J., Song, Y. M., Park, K. C., Choi, S. H., Kim, N. D., Yoon, J. H., Mungai, P. T., Schumacker, P. T., and Kwon, H. J. (2010) Terpestacin Inhibits Tumor Angiogenesis by Targeting UQCRB of Mitochondrial Complex III and Suppressing Hypoxia-induced Reactive Oxygen Species Production and Cellular Oxygen Sensing. J. Biol. Chem. 285, 11584−11595. (7) Kim, H., Deng, L., Xiong, X., Hunter, W. D., Long, M. C., and Pirrung, M. C. (2007) Glyceraldehyde 3-Phosphate Dehydrogenase Is a Cellular Target of the Insulin Mimic Demethylasterriquinone B1. J. Med. Chem. 50, 3423−3426. (8) Kim, N. H., Pham, N. B., Quinn, R. J., Shim, J. S., Cho, H., Cho, S. M., Park, S. W., Kim, J. H., Seok, S. H., Oh, J.-W., and Kwon, H. J. (2015) The small molecule R-(−)-β-O-methylsynephrine binds to nucleoporin 153 kDa and inhibits angiogenesis. Int. J. Biol. Sci. 11, 1088−1099. (9) Piggott, A. M., and Karuso, P. (2008) Rapid Identification of a Protein Binding Partner for the Marine Natural Product Kahalalide F by Using Reverse Chemical Proteomics. ChemBioChem 9, 524−530. (10) Piggott, A. M., Kriegel, A. M., Willows, R. D., and Karuso, P. (2009) Rapid isolation of novel FK506 binding proteins from multiple organisms using gDNA and cDNA T7 phage display. Bioorg. Med. Chem. 17, 6841−6850. (11) Shim, J. S., Lee, J., Park, H.-J., Park, S.-J., and Kwon, H. J. (2004) A New Curcumin Derivative, HBC, Interferes with the Cell Cycle Progression of Colon Cancer Cells via Antagonization of the Ca2+/Calmodulin Function. Chem. Biol. 11, 1455−1463. (12) Woolard, J., Vousden, W., Moss, S. J., Krishnakumar, A., Gammons, M. V. R., Nowak, D. G., Dixon, N., Micklefield, J., Spannhoff, A., Bedford, M. T., Gregory, M. A., Martin, C. J., Leadlay, P. F., Zhang, M. Q., Harper, S. J., Bates, D. O., and Wilkinson, B. (2011) Borrelidin modulates the alternative splicing of VEGF in favor of anti-angiogenic isoforms. Chem. Sci. 2, 273−278. (13) Gotsbacher, M. P., Cho, S., Kwon, H. J., and Karuso, P. (2016) Daptomycin, a last-resort antibiotic, binds ribosomal protein S19 in humans. Proteome Sci. 15, 16. (14) Tu, Y. (2016) ArtemisininA Gift from Traditional Chinese Medicine to the World (Nobel Lecture). Angew. Chem., Int. Ed. 55, 10210. (15) Klayman, D. L. (1985) Qinghaosu (artemisinin): an antimalarial drug from China. Science 228, 1049−1055. (16) White, N. J. (2008) Qinghaosu (Artemisinin): The Price of Success. Science 320, 330−334. (17) O’Neill, P. M., Barton, V. E., and Ward, S. A. (2010) The molecular mechanism of action of artemisinin - the debate continues. Molecules 15, 1705−1721. (18) Stocks, P. A., Bray, P. G., Barton, V. E., Al-Helal, M., Jones, M., Araujo, N. C., Gibbons, P., Ward, S. A., Hughes, R. H., Biagini, G. A., Davies, J., Amewu, R., Mercer, A. E., Ellis, G., and O’Neill, P. M. (2007) Evidence for a Common Non-Heme Chelatable-IronDependent Activation Mechanism for Semisynthetic and Synthetic Endoperoxide Antimalarial Drugs. Angew. Chem., Int. Ed. 46, 6278− 6283. (1) in several human cancer proteomes displayed on bacteriophage T7 and shown that a possible mode of action is to interfere with BAD phosphorylation at S136. This BADtargeting activity of 1 is highly synergistic with the BH3 mimetic ABT-737 that binds Bcl-xL. Biophysical characterization of the interaction between ART and BAD was made difficult because BAD is an intrinsically disordered protein. Identifying and quantifying such weak and dynamic interactions is problematic, and biophysical evidence is usually more ambiguous than for globular proteins. However, these atypical and often weak interactions, refractory to in vivo characterization, can be very meaningful in higher-order signaling assemblies and regulation that is only now being appreciated.64 However, overall, our data suggest a targeted mechanism of action for 1 for immediate clinical exploitation.50 ■ ASSOCIATED CONTENT S Supporting Information * The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acschembio.8b01004. ■ Methods section, including detailed synthetic procedures and probe stability, detailed target identification and validation procedures, and synergistic activity data (PDF) AUTHOR INFORMATION Corresponding Authors *E-mail: peter.karuso@mq.edu.au. *E-mail: kwonhj@yonsei.ac.kr. ORCID Michael P. Gotsbacher: 0000-0002-7153-1250 Sung Min Cho: 0000-0003-1889-6370 Ho Jeong Kwon: 0000-0002-6919-833X Peter Karuso: 0000-0002-0217-6021 Present Address § M.P.G.: School of Medical Sciences (Pharmacology), The University of Sydney, Sydney, NSW 2006, Australia. Author Contributions ⊥ M.P.G. and S.M.C. contributed equally. Funding This work was supported by ARC grant DP130103281 to P.K. and H.J.K. and NRF grants 2015K1A1A2028365, 2015M3A9C4076321, and BK21plus to H.J.K. Notes The authors declare no competing financial interest. ■ ABBREVIATIONS BAD, Bcl-2 antagonist of cell death; pBAD, S136 phosphorylated BAD; siBAD, a mixture of four specific small interfering RNAs against BAD; ART, artesunate; F-ART, fluorescent ART ■ REFERENCES (1) Mathivet, P., Bernasconi, R., Barry, J. D., Marescaux, C., and Bittiger, H. (1997) Binding characteristics of γ-hydroxybutyric acid as a weak but selective GABAB receptor agonist. Eur. J. Pharmacol. 321, 67−75. (2) Keilhauer, E. C., Hein, M. Y., and Mann, M. (2015) Accurate Protein Complex Retrieval by Affinity Enrichment Mass Spectrometry 641 DOI: 10.1021/acschembio.8b01004 ACS Chem. Biol. 2019, 14, 636−643 Articles ACS Chemical Biology conformational change upon binding to prosurvival Bcl-2 targets. Cell Death Differ. 14, 128−136. (37) Yang, E., Zha, J., Jockel, J., Boise, L. H., Thompson, C. B., and Korsmeyer, S. J. (1995) Bad, a heterodimeric partner for Bcl-xL and Bcl-2, displaces bax and promotes cell death. Cell 80, 285−291. (38) Lomenick, B., Hao, R., Jonai, N., Chin, R. M., Aghajan, M., Warburton, S., Wang, J., Wu, R. P., Gomez, F., Loo, J. A., Wohlschlegel, J. A., Vondriska, T. M., Pelletier, J., Herschman, H. R., Clardy, J., Clarke, C. F., and Huang, J. (2009) Target identification using drug affinity responsive target stability (DARTS). Proc. Natl. Acad. Sci. U. S. A. 106, 21984−21989. (39) Pommier, Y. (2006) Topoisomerase I inhibitors: camptothecins and beyond. Nat. Rev. Cancer 6, 789−802. (40) Efferth, T. (2014) Activation of Mitochondria-Driven Pathways by Artemisinin and Its Derivatives. In Mitochondria: The Anti-cancer Target for the Third Millennium (Neuzil, J., Pervaiz, S., and Fulda, S., Eds.), pp 135−150, Springer, Netherlands. (41) Tran, K. Q., Tin, A. S., and Firestone, G. L. (2014) Artemisinin triggers a G1 cell cycle arrest of human Ishikawa endometrial cancer cells and inhibits cyclin-dependent kinase-4 promoter activity and expression by disrupting nuclear factor-κB transcriptional signaling. Anti-Cancer Drugs 25, 270−281. (42) Efferth, T., Sauerbrey, A., Olbrich, A., Gebhart, E., Rauch, P., Weber, H. O., Hengstler, J. G., Halatsch, M.-E., Volm, M., Tew, K. D., Ross, D. D., and Funk, J. O. (2003) Molecular modes of action of artesunate in tumor cell lines. Mol. Pharmacol. 64, 382−394. (43) Button, R. W., Lin, F., Ercolano, E., Vincent, J. H., Hu, B., Hanemann, C. O., and Luo, S. (2014) Artesunate induces necrotic cell death in schwannoma cells. Cell Death Dis. 5, No. e1466. (44) Ooko, E., Saeed, M. E. M., Kadioglu, O., Sarvi, S., Colak, M., Elmasaoudi, K., Janah, R., Greten, H. J., and Efferth, T. (2015) Artemisinin derivatives induce iron-dependent cell death (ferroptosis) in tumor cells. Phytomedicine 22, 1045−1054. (45) Zhou, Y., Li, W., and Xiao, Y. (2016) Profiling of Multiple Targets of Artemisinin Activated by Hemin in Cancer Cell Proteome. ACS Chem. Biol. 11 (4), 882−888. (46) Qin, G., Wu, L., Liu, H., Pang, Y., Zhao, C., Wu, S., Wang, X., and Chen, T. (2015) Artesunate induces apoptosis via a ROSindependent and Bax-mediated intrinsic pathway in HepG2 cells. Exp. Cell Res. 336, 308−317. (47) Zhang, F., Gosser, D. K., and Meshnick, S. R. (1992) Hemincatalyzed decomposition of artemisinin (qinghaosu). Biochem. Pharmacol. 43, 1805−1809. (48) Czabotar, P. E., Lessene, G., Strasser, A., and Adams, J. M. (2014) Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat. Rev. Mol. Cell Biol. 15, 49−63. (49) Adams, J. M., and Cory, S. (2007) The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 26, 1324−1337. (50) Crespo-Ortiz, M. P., and Wei, M. Q. (2012) Antitumor activity of artemisinin and its derivatives: from a well-known antimalarial agent to a potential anticancer drug. J. Biomed. Biotechnol. 2012, 247597. (51) Leo, C. P., Hsu, S. Y., Chun, S. Y., Bae, H. W., and Hsueh, A. J. (1999) Characterization of the antiapoptotic Bcl-2 family member myeloid cell leukemia-1 (Mcl-1) and the stimulation of its message by gonadotropins in the rat ovary. Endocrinology 140, 5469−5477. (52) Danial, N. N., and Korsmeyer, S. J. (2004) Cell death: critical control points. Cell 116, 205−219. (53) She, Q. B., Solit, D. B., Ye, Q., O’Reilly, K. E., Lobo, J., and Rosen, N. (2005) The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells. Cancer Cell 8, 287−297. (54) Andreeff, M., Jiang, S., Zhang, X., Konopleva, M., Estrov, Z., Snell, V. E., Xie, Z., Okcu, M. F., Sanchez-Williams, G., Dong, J., Estey, E. H., Champlin, R. C., Kornblau, S. M., Reed, J. C., and Zhao, S. (1999) Expression of Bcl-2-related genes in normal and AML progenitors: changes induced by chemotherapy and retinoic acid. Leukemia 13, 1881−1892. (1 9) I s ma il , H. M ., B art o n, V . E., P an chan a, M. , Charoensutthivarakul, S., Biagini, G. A., Ward, S. A., and O’Neill, P. M. (2016) A Click Chemistry-Based Proteomic Approach Reveals that 1,2,4-Trioxolane and Artemisinin Antimalarials Share a Common Protein Alkylation Profile. Angew. Chem., Int. Ed. 55, 6401−6405. (20) Robert, A., Cazelles, J., and Meunier, B. (2001) Characterization of the Alkylation Product of Heme by the Antimalarial Drug Artemisinin. Angew. Chem., Int. Ed. 40, 1954−1957. (21) Wang, J., Zhang, C.-J., Chia, W. N., Loh, C. C. Y., Li, Z., Lee, Y. M., He, Y., Yuan, L.-X., Lim, T. K., Liu, M., Liew, C. X., Lee, Y. Q., Zhang, J., Lu, N., Lim, C. T., Hua, Z.-C., Liu, B., Shen, H.-M., Tan, K. S. W., and Lin, Q. (2015) Haem-activated promiscuous targeting of artemisinin in Plasmodium falciparum. Nat. Commun. 6, 10111. (22) Eckstein-Ludwig, U., Webb, R. J., van Goethem, I. D. A., East, J. M., Lee, A. G., Kimura, M., O’Neill, P. M., Bray, P. G., Ward, S. A., and Krishna, S. (2003) Artemisinins target the SERCA of Plasmodium falciparum. Nature 424, 957−961. (23) Lisewski, A. M., Quiros, J. P., Ng, C. L., Adikesavan, A. K., Miura, K., Putluri, N., Eastman, R. T., Scanfeld, D., Regenbogen, S. J., Altenhofen, L., Llinas, M., Sreekumar, A., Long, C., Fidock, D. A., and Lichtarge, O. (2014) Supergenomic network compression and the discovery of EXP1 as a glutathione transferase inhibited by artesunate. Cell 158, 916−928. (24) Mbengue, A., Bhattacharjee, S., Pandharkar, T., Liu, H., Estiu, G., Stahelin, R. V., Rizk, S. S., Njimoh, D. L., Ryan, Y., Chotivanich, K., Nguon, C., Ghorbal, M., Lopez-Rubio, J. J., Pfrender, M., Emrich, S., Mohandas, N., Dondorp, A. M., Wiest, O., and Haldar, K. (2015) A molecular mechanism of artemisinin resistance in Plasmodium falciparum malaria. Nature 520, 683−687. (25) Efferth, T., Dunstan, H., Sauerbrey, A., Miyachi, H., and Chitambar, C. R. (2001) The anti-malarial artesunate is also active against cancer. Int. J. Oncol. 18, 767−773. (26) Singh, N. P., and Lai, H. C. (2004) Artemisinin induces apoptosis in human cancer cells. Anticancer Res. 24, 2277−2280. (27) Efferth, T. (2006) Molecular pharmacology and pharmacogenomics of artemisinin and its derivatives in cancer cells. Curr. Drug Targets 7, 407−421. (28) Ho, W. E., Peh, H. Y., Chan, T. K., and Wong, W. S. F. (2014) Artemisinins: Pharmacological actions beyond anti-malarial. Pharmacol. Ther. 142, 126−139. (29) Lai, H. C., Singh, N. P., and Sasaki, T. (2013) Development of artemisinin compounds for cancer treatment. Invest. New Drugs 31, 230−246. (30) Kwok, J. C., and Richardson, D. R. (2002) The iron metabolism of neoplastic cells: alterations that facilitate proliferation? Crit. Rev. Oncol. Hematol. 42, 65−78. (31) Efferth, T. (2007) Willmar Schwabe Award 2006: antiplasmodial and antitumor activity of artemisinin - from bench to bedside. Planta Med. 73, 299−309. (32) Huang, C., Ba, Q., Yue, Q., Li, J., Li, J., Chu, R., and Wang, H. (2013) Artemisinin rewires the protein interaction network in cancer cells: network analysis, pathway identification, and target prediction. Mol. BioSyst. 9, 3091−3100. (33) Odaka, Y., Xu, B., Luo, Y., Shen, T., Shang, C., Wu, Y., Zhou, H., and Huang, S. (2014) Dihydroartemisinin inhibits the mammalian target of rapamycin-mediated signaling pathways in tumor cells. Carcinogenesis 35, 192−200. (34) Thanaketpaisarn, O., Waiwut, P., Sakurai, H., and Saiki, I. (2011) Artesunate enhances TRAIL-induced apoptosis in human cervical carcinoma cells through inhibition of the NF-κB and PI3K/ Akt signaling pathways. Int. J. Oncol. 39, 279−285. (35) Cho, S., Oh, S., Um, Y., Jung, J.-H., Ham, J., Shin, W.-S., and Lee, S. (2009) Synthesis of 10-substituted triazolyl artemisinins possessing anticancer activity via Huisgen 1,3-dipolar cylcoaddition. Bioorg. Med. Chem. Lett. 19, 382−385. (36) Hinds, M. G., Smits, C., Fredericks-Short, R., Risk, J. M., Bailey, M., Huang, D. C., and Day, C. L. (2007) Bim, Bad and Bmf: intrinsically unstructured BH3-only proteins that undergo a localized 642 DOI: 10.1021/acschembio.8b01004 ACS Chem. Biol. 2019, 14, 636−643 Articles ACS Chemical Biology (55) Datta, S. R., Dudek, H., Tao, X., Masters, S., Fu, H., Gotoh, Y., and Greenberg, M. E. (1997) Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91, 231− 241. (56) del Peso, L., Gonzalez-Garcia, M., Page, C., Herrera, R., and Nunez, G. (1997) Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science 278, 687−689. (57) Donovan, N., Becker, E. B., Konishi, Y., and Bonni, A. (2002) JNK phosphorylation and activation of BAD couples the stressactivated signaling pathway to the cell death machinery. J. Biol. Chem. 277, 40944−40949. (58) Zha, J., Harada, H., Yang, E., Jockel, J., and Korsmeyer, S. J. (1996) Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not Bcl-x(L). Cell 87, 619− 628. (59) Oltersdorf, T., Elmore, S. W., Shoemaker, A. R., Armstrong, R. C., Augeri, D. J., Belli, B. A., Bruncko, M., Deckwerth, T. L., Dinges, J., Hajduk, P. J., Joseph, M. K., Kitada, S., Korsmeyer, S. J., Kunzer, A. R., Letai, A., Li, C., Mitten, M. J., Nettesheim, D. G., Ng, S. C., Nimmer, P. M., O’Connor, J. M., Oleksijew, A., Petros, A. M., Reed, J. C., Shen, W., Tahir, S. K., Thompson, C. B., Tomaselli, K. J., Wang, B., Wendt, M. D., Zhang, H., Fesik, S. W., and Rosenberg, S. H. (2005) An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435, 677−681. (60) Luo, J., Zhu, W., Tang, Y., Cao, H., Zhou, Y., Ji, R., Zhou, X., Lu, Z., Yang, H., Zhang, S., and Cao, J. (2014) Artemisinin derivative artesunate induces radiosensitivity in cervical cancer cells in vitro and in vivo. Radiat. Oncol. 9, 84. (61) Chen, T., Li, M., Zhang, R., and Wang, H. (2009) Dihydroartemisinin induces apoptosis and sensitizes human ovarian cancer cells to carboplatin therapy. J. Cell. Mol. Med. 13, 1358−1370. (62) Wang, B., Hou, D., Liu, Q., Wu, T., Guo, H., Zhang, X., Zou, Y., Liu, Z., Liu, J., Wei, J., Gong, Y., and Shao, C. (2015) Artesunate sensitizes ovarian cancer cells to cisplatin by downregulating RAD51. Cancer Biol. Ther. 16, 1548−1556. (63) Chen, K., Shou, L.-M., Lin, F., Duan, W.-M., Wu, M.-Y., Xie, X., Xie, Y.-F., Li, W., and Tao, M. (2014) Artesunate induces G2/M cell cycle arrest through autophagy induction in breast cancer cells. AntiCancer Drugs 25, 652−662. (64) Berlow, R. B., Dyson, H. J., and Wright, P. E. (2018) Expanding the Paradigm: Intrinsically Disordered Proteins and Allosteric Regulation. J. Mol. Biol. 430, 2309−2320. 643 DOI: 10.1021/acschembio.8b01004 ACS Chem. Biol. 2019, 14, 636−643
Purchase answer to see full attachment
Student has agreed that all tutoring, explanations, and answers provided by the tutor will be used to help in the learning process and in accordance with Studypool's honor code & terms of service.

Explanation & Answer

Hi dude, I am sending you your homework. Text me if you need additional improvements.

Manuscripts summary
The manuscript entitled “Reverse Chemical Proteomics Identifies an Unanticipated Human
Target of the Antimalarial Artesunate” revealed the ability of artesunate (ART) (a drug used
to treat malaria) to inhibit the phosphorylation of Bcl-2 agonist of cell death (BAD). In this
way, the formulation of a proapoptotic BAD/Bcl-xL complex is being realized which results
in cell death as a consequence of subsequence intrinsic apoptotic cascade. The intrinsic
apoptotic involves cytochrome c release, PARP cleavage, caspase activation. In the
mentioned study the identification of the BAD promotor was reported. For this purpose, the
T7 phage display was used. The usage of phage display to study protein-protein, proteinpeptide, and protein–DNA interactions is an attractive approach in comparison to the other
techniques (affinity capture MS or affinity chromatography). T7 phage display is particularly
suited for weak interactions with low abundance proteins. The use of ART is not limited to
malaria control; also ART has demonstrated anticancer activity and promoting apoptosis.
The experimental part of the study started with the synthesis of biotinylated analogue of
artesunate by using artemisinin which contained a long, hydrophilic linker. Additionally, the
fluorescent analog of artesunate (F-ART) was synthesized for imaging. ...

qlanzvp_ghgbe (508)
Carnegie Mellon University

Anonymous
Goes above and beyond expectations!

Studypool
4.7
Trustpilot
4.5
Sitejabber
4.4

Related Tags